LTTS Partners with NVIDIA to Develop AI-Powered Digital Twin Platform for Respiratory Diagnostics

LTTS Unveils NVIDIA-Powered Digital Twin Platform for Advanced Respiratory Diagnostics | AIM

The collaboration brings together LTTS' expertise in MedTech and NVIDIA AI infrastructure to deliver precision diagnostics and enhance patient care. L&T Technology Services (LTTS) has announced the development of a next-generation AI-powered digital twin platform for respiratory diagnostics and lung navigation, developed in collaboration with NVIDIA. The company said the platform aims to deliver scalable, low-latency solutions that improve diagnostic precision and expand access to advanced imaging tools for clinicians worldwide. The solution, to be showcased at the Radiological Society of North America (RSNA) 2025 conference, integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy. Built on NVIDIA MONAI for medical image segmentation and NVIDIA TensorRT for optimised AI inference, the platform enables detailed visualisation of airways, blood vessels, lobes and lesions, along with interactive simulation and path-planning support for bronchoscopy procedures. LTTS said its engineering capabilities in medical imaging and proprietary navigation systems allow static CT scans to be converted into dynamic, clinically meaningful digital representations that evolve with patient data. The company said such biological digital twins can support planning and navigation for conditions including lung cancer, COPD and infectious diseases. "AI is reshaping what's possible in diagnostics and medical technology," said Alind Saxena, executive director and president of mobility and tech at LTTS. "Our collaboration with NVIDIA combines LTTS' expertise in AI-driven diagnostics and predictive analytics, with NVIDIA's powerful modeling and visualisation platform. This lets us engineer a digital twin platform that not only enhances diagnostic accuracy but also gives clinicians an immersive, real-time planning tool ultimately helping deliver better outcomes for patients around the world," Saxena added. David Niewolny, director of business development for healthcare/medical at NVIDIA, said the partnership demonstrates the potential for accelerated computing in clinical workflows. "Working with LTTS to accelerate the development of AI-enabled medical technology demonstrates how NVIDIA is empowering the healthcare industry with accelerated computing and AI innovation," Niewolny said. "LTTS is enabling transformative solutions that bring the vision of real-time AI and biological digital twins powered by NVIDIA to clinical practice, delivering interactive, real-time visualisation and intelligent guidance to help clinicians provide higher-quality care and achieve better outcomes for patients."

L&T Tech Taps Nvidia AI To Build 3D 'Digital Twins' For Lung Cancer Diagnostics - NVIDIA (NASDAQ:NVDA)

L&T Technology Services on Monday announced that it has developed a next-generation artificial intelligence-powered digital twin platform designed to improve respiratory diagnostics and lung navigation. Leveraging its strengths in platform engineering, connected health, advanced imaging, and AI diagnostics -- and running on Nvidia's accelerated computing technology -- L&T Technology Services plans to deliver scalable, low-latency solutions that boost diagnostic accuracy and expand access for healthcare providers. L&T Technology Services will debut the platform at the Radiological Society of North America (RSNA) 2025. Also Read: Nvidia And Fujitsu Team Up To Build AI Systems For The Future The system integrates with CT imaging and uses deep learning to create a 3D digital twin of a patient's lungs With support from Nvidia Medical Open Network for AI (MONAI) for medical image segmentation and Nvidia TensorRT for efficient AI inference, clinicians can visualize anatomy interactively, plan procedures, and navigate bronchoscopies with greater precision. By converting scans into dynamic models that evolve with patient health, L&T Technology Services applies its medical imaging and navigation expertise to support improved treatment planning for lung cancer, chronic obstructive pulmonary disease (COPD), and infectious diseases. Nvidia is rapidly expanding its footprint in healthcare AI, moving far beyond its gaming and graphics processing unit roots. Analyst Take At JP Morgan's Healthcare Conference, analyst Harlan Sur said Nvidia is positioned to capitalize on soaring demand for automation and AI in hospitals. The company is rolling out AI "digital health agents," including delivery robots and generative AI tools for clinical communication, to help address a projected shortage of up to 20 million healthcare workers. Partnerships with firms like Intrivo and Abridge are already putting these technologies into real-world use. Sur also pointed to Nvidia's datacenter platforms -- Omniverse, Cosmos and DGX Cloud -- which are accelerating AI adoption in medicine through flexible deployment options. He expects Nvidia's healthcare business to generate about $1 billion in annual recurring revenue by fiscal 2026. Nvidia continues to embed AI across drug discovery, robotic surgery and genomics through new collaborations with Iqvia and Illumina, a strategy Sur said strengthens its push to lead the healthcare AI market. If his projections prove out, healthcare could become Nvidia's next billion-dollar frontier. NVDA Price Action: Nvidia shares were down 1.76% at $173.88 during premarket trading on Friday, according to Benzinga Pro data. Read Next: Oracle And Nvidia Team Up To Power Abu Dhabi's Push For 'Sovereign AI' Photo by Below the Sky via Shutterstock NVDANVIDIA Corp$173.60-1.92%OverviewMarket News and Data brought to you by Benzinga APIs